By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer This is the third blog post of our ongoing “Understanding Lung Cancer” series. This series aims to simplify the science behind lung cancer and help provide a deeper understanding [...]
Tamika R. was diagnosed with stage 4 (IV) metastatic lung cancer that had spread to the brain at just 48 years old. She is now retired from re-entry corrections with the goal of giving her grandchildren the rest of [...]
On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) who [...]
On October 3, 2024, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) to be used with platinum-doublet chemotherapy as a treatment before surgery, followed by Opdivo (nivolumab) alone after surgery. This approval is for people with resectable (removable [...]
On August 15, 2024, the U.S. Food and Drug Administration (FDA) granted approval for the immunotherapy drug Imfinzi (durvalumab) to be used in combination with chemotherapy (neoadjuvant, treatment given before surgery) as well as on its own after surgery (adjuvant). [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring. At this meeting, oncologists, physicians, researchers, industry members, advocacy organizations (like GO2,) patients, and caregivers come together to share and learn about the latest and most [...]
Author: GO2 for Lung Cancer Specialist, Science & Research, Brittney Nichols MPH, BSN-RN Each year, scientists and doctors from across the globe gather at IASLC’s World Conference on Lung Cancer (WCLC) to discuss the latest and greatest in lung [...]
Every year, lung cancer professionals from across the globe gather to connect and learn at the World Conference for Lung Cancer (WCLC). Members of the GO2 team just returned from WCLC 2023 hosted in Singapore, where they presented GO2’s [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring where oncologists and other physicians, researchers, industry members, and advocacy organizations like GO2 come together to share and learn the latest and most exciting news on [...]
By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from [...]